Every year Fortune 500 publishes its list of the 500 largest companies in the United States, ranked by the annual revenues for the previous fiscal year. Fortune has been publishing its listing of the ‘Fortune 500’ for 67 years, and inclusion on its annual list is considered to be a mark of prestige.
This year 41 of the 500 companies were led by women CEOs and included two Black women. Since the list is seen as a microcosm of the U.S. business community at large, statistics such as these are closely monitored by those who are tracking diversity in the business community.
Followers of the business world are interested to discover some of the most vibrant women CEOs on the 2021 Fortune 500 list. So put your Springbok mobile gameplay aside for a few minutes and get all the info here. These amazing women include:
Former Aetna president Karen Lynch took over as CEO of CVS Health this year. CVS ranks #4 on the 2021 Fortune 500 list and is the largest company ever to be run by a female chief executive.
Roz Brewer is a new name on the Fortune 500 list of CEOs. She is a former executive at Starbucks and is now CEO of Walgreens Boots Alliance. Brewer is one of two Black women to be running a Fortune 500 company. The Detroit native attended Spelman College, Stanford Law School, and the Booth School of Business at the University of Chicago.
She is also a graduate of the Wharton School of the University of Pennsylvania, where she has a degree from the Advanced Management Program. She was named by Forbes Magazine as one of the ‘World’s 100 Most Powerful Women’ in 2020.
Brewer is seen as a global business leader and as a high-impact strategist. She was CEO of Sam’s Club before moving to Starbucks and then to Walgreens Boots Alliance. She is credited with focusing Sam’s Club on growing membership, amplifying the use of digital technology, and transforming merchandise which led to the company’s growth during her years at its head.
Her career has included experience in R&D, strategic business unit leadership, marketing, and manufacturing operations. She excels in building strong teams and inspiring mentoring networks. Brewer attributes her success to her ability to balance family, work, and community.
Jane Fraser is the Chief Executive Officer of Citi and oversees its branches in 160 countries and jurisdictions. Prior to being named Citi CEO, Fraser was President of Citi. Her expertise included Credit Cards, Retail Banking, and Wealth Management, Operations and Technology, and Mortgages for Citi’s Consumer businesses as CEO of the Global Consumer Bank. Other experience includes Fraser’s terms as CEO of Citigroup Latin America, Global Head of Strategy and Mergers & Acquisitions for Citi, CEO of U.S. Consumer and Commercial Banking, and CEO of Citi’s Global Private Bank.
Fraser attended the University of Cambridge, where she received an M.A. in economics, and Harvard Business School, where she received an MBA. Currently, she is Vice-Chair for the partnership for New York City and serves on the Harvard Business School’s Board of Dean’s Advisors.
Dick’s Sporting Goods Inc., in the midst of an upsurge in demand as athletic gear sales jump, named Lauren Hobert as its new CEO. Hobart attended the University of Pennsylvania and then got her MBA from the Stanford University Graduate School of Business. Before joining Dicks she was the eEVP, Chief Marketing Officer, Chief Customer & Digital Officer at SVP, where she also worked in Marketing, E-Commerce, and the Team Sports H.Q. digital ecosystem. She has also worked for Wells Fargo, JP Morgan, Chase, and Pepsi Co.
Hobart’s strategy since her appointment has taken the form of unleashing a number of initiatives to attract more shoppers, inspire consumers and expand its physical footprint. The moves have proved successful, and since she became CEO last November, Dick’s posted earnings and sales have increased 45%.
Dr. Reshma Kewalramani has taken the lead at Vertex Pharmaceuticals, where she is serving as the CEO and President. Dr. Kewalramani received her medical degree, with honors, from the Boston University School of Medicine. She completed her internship and residency at the Massachusetts General Hospital in Internal Medicine and a fellowship in Nephrology in a combined program involving the Massachusetts General Hospital and Brigham and Women’s Hospital. Dr. Kewalramani also completed the General Management Program at Harvard Business School.
Dr. Kewalramani has specialized in the development of new medicines during her career. Previously she was Chief Medical Officer of Global Medicines Development and Medical Affairs. She intends to move forward with Vermex in their treatments for cystic fibrosis (C.F.) patients, including the approval of SYMDEKO/SYMKEVI and TRIKAFTA. Other Vermex developments during her term have included drugs to treat APOL1-mediated kidney diseases, alpha-1 antitrypsin deficiency, sickle cell disease, and beta-thalassemia.
Dr. Kewalramani is active in RIZE Massachusetts, a nonprofit foundation focused on ending the opioid epidemic, and in the Biomedical Science Careers Program, an organization dedicated to supporting underrepresented students to pursue a career in STEM. She is a Fellow of the American Society of Nephrology and is a member of the Boston University School of Medicine Dean’s Advisory Board.
Adena T. Friedman is the current President and CEO of NASDAQ, where she had previously held the position of President of Global Corporate and information technology solutions. She is the first woman to lead a global exchange.
Friedman has been named by Forbes as one of the world’s most powerful women on their annual Power Women list.
Friedman attended Williams College and then the Owen School of Business at Vanderbilt University. She was the Chief Financial Officer at NASDAQ for seven years and then moved to the Carlyle Group. She returned to NASDAQ in 2014 and took the position of President and CEO in 2017.
Friedman’s goal is to modernize NASDAQ by making investing more accessible to the public market. She wants to diversify NASDAQ into a tech company and focus on data research services and other growth opportunities. She is also a proponent of corporate diversity and has asked the SEC to require companies listed on its exchange to publish data on board diversity.
Friedman is also on the Board of the N.Y. Federal Reserve.